Danish psychiatric research hospital will study the effects of Filament's natural psilocybin drug candidate for treating alcohol use disorder
"Alcohol use disorder is a widespread issue for global public health and constitutes a major risk factor for disability and mortality," said
Five percent of all deaths worldwide each year result from the harmful use of alcohol. With this trial, Psychiatric Centre Copenhagen will determine the effects of a single administration of 25 milligrams of psilocybin on alcohol use and study the extent to which the brain is affected by psilocybin.
"Psychiatric Centre Copenhagen is an internationally recognized psychiatric research institution," said
This is the third European clinical trial which has been approved to use Filament's natural psilocybin. The trial in
Learn more at www.filament.health and on Twitter, Instagram, and LinkedIn.
Certain statements and information contained herein may constitute "forward–looking statements" and "forward–looking information," respectively, under Canadian securities legislation. Generally, forward–looking information can be identified by the use of forward–looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward–looking statements or information. The forward–looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward–looking statements. Forward–looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward–looking statements or forward–looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward– looking statements and forward–looking information. Filament will not update any forward– looking statements or forward–looking information that are incorporated by reference herein, except as required by applicable securities laws.
SOURCE
© Canada Newswire, source